Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G2B011
- Development stage
- Preclinical
- Lead developer
- G2B Pharma
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
G2B011 is a needle-free, dry powder nasal formulation of epinephrine developed for the emergency treatment of anaphylaxis. The product utilizes Shin Nippon Biomedical Laboratories' (SNBL) proprietary **µco™ System** nasal delivery platform and the **Fit-lizer™** nasal device, which are designed to facilitate rapid absorption of the drug through the nasal mucosa. Originally developed by G2B Pharma with project financing from Sosei Group, the intellectual property and assets for G2B011 were acquired by StellaPharma in 2021. The drug aims to provide a more patient-friendly and portable alternative to traditional epinephrine auto-injectors, potentially improving compliance and ease of use for patients at risk of severe allergic reactions.
- Other names
- epinephrine nasal powdernasal epinephrine dry powderepinephrine
02
Targets
ADRA1A (α1A)ADRA2A (α2A)ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on G2B011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G2B011.